Clinical trial
Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI…
NCT00410943 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00410943 |
|---|---|
| Title | Study of the Effectiveness and Tolerability of OROS Hydromorphone HCI SR(Slow-release) Tablets and Immediate-Release Hydromorphone Tablets in Patients With Chronic Pain |
| Official title | A Randomized, Double-Blind, Repeated Dose, Parallel-Group Comparison of the Efficacy & Tolerability of Dilaudid SR Tablets and Immediate Release Dilaudid Tablets (Hydromorphone HCI) in Patients With Chronic Pain |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain |
| Intervention type | Drug |
| Interventions | OROS Hydromorphone HCI SR (slow release) |
| Enrollment | 169 |
| Completion | Jun 1, 1999 |
| First posted | Dec 13, 2006 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: